Isomorphic Labs, Alphabet's AI-powered drug discovery company led by Nobel laureate Demis Hassabis, completed a $5 billion Series C funding round co-led by Greenoaks and Sequoia Capital. New investors including Andreessen Horowitz (a16z) joined the round, while Alphabet continued its substantial capital commitment alongside existing backers Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The company plans to deploy the capital to advance foundational simulation models, scale internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.